This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
HAIFA, Israel, June 20, 2013 (GLOBE NEWSWIRE) --
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that preclinical results for its Placental eXpanded (PLX) RAD cells in the treatment of bone marrow disease have been published in peer reviewed journal PLOS ONE.
A study titled "Mitigation of lethal radiation syndrome in mice by intramuscular injection of 3D cultured adherent human placental stromal cells" was published on June 18th in the open access journal PLOS ONE (
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0066549 ). This animal study on acute radiation syndrome (ARS) was performed by Professor Raphael Gorodetsky and his team at the Biotechnology and Radiobiology Laboratory at the Sharett Institute of Oncology at Hadassah Medical Center, Jerusalem in collaboration and the support of Pluristem Therapeutics. The findings of the published study suggest that intramuscular treatment with Pluristem's PLX-RAD cells may serve as a highly effective "off the shelf" therapy to mitigate ARS.
The treatment of intramuscular injection of PLX-RAD cells increased the survival of 7.7Gy irradiated mice from about 27% to about 98% (P<0.0001). The treated mice regained their weight significantly faster than the few survivors of the controls. The treatment stimulated extensive hematopoietic stem cells (HSC) proliferation to enable the speedy recovery of the radiation induced depleted bone marrow with parallel increase the number of circulating white blood cells, red blood cells and platelets. The number of CD45+/SCA1+ hematopoietic progenitor cells within the fast recovering population of nucleated bone marrow cells in the irradiated mice was also elevated in the mice treated with PLX-RAD cells.
Prof. Raphael Gorodetsky commented: "The intramuscular injection of PLX-RAD significantly increased the survival of animals exposed to high lethal doses of total body irradiation even when treatment was delayed by more than 24 hrs after exposure. Therefore, our study points for the application of such treatments in scenarios of nuclear accidents involving numerous casualties also in remote disaster areas."